Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular Endpoint
Question
Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular Endpoint
Direct answer
Negative clinical trial results eliminate future commercial royalty cash flows for IONS and compress RPRX valuation, while removing a pipeline growth driver for NVS. — bearish pressure on IONS via milestone and downstream royalty cash flow loss.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-05
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular Endpoint”, revision 1, evidence through 2026-09-05. https://marketontology.com/catalysts/2026-09-05/novartis-phase-3-pelacarsen-trial-fails-primary-cardiovascular-endpoint-e3b904
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| IONS | ▼Bear | 1–5 days | milestone and downstream royalty cash flow loss | 53 |
| NVS | ▼Bear | 1–5 days | cardiovascular pipeline revenue write-down | 51 |
Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular Endpoint
Negative clinical trial results eliminate future commercial royalty cash flows for IONS and compress RPRX valuation, while removing a pipeline growth driver for NVS. — bearish pressure on IONS via milestone and downstream royalty cash flow loss.
Ionis partnered asset failed pivotal Phase 3 endpoint
- SourceIonis partnered asset failed pivotal Phase 3 endpoint
- TransmissionNegative clinical trial results eliminate future commercial royalty cash flows for IONS and compress RPRX valuation, while removing a pipeline growth driver for NVS.
- SummaryNovartis' Phase 3 HORIZON trial for pelacarsen failed to reduce cardiovascular events. Royalty Pharma expects to recoup its $500 million capital investment despite the trial outcome. The failure affects commercialization prospects for lipoprotein(a)-lowering therapies.
- IONSDirect directional or hedged short
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- Fed officials or competing data may reframe the print
- IONS closes above pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- IONS price vs. pre-event level
- IONS volume vs. 20-day average
- 2Y/10Y Treasury yield direction
- DXY direction
- Fed funds futures repricing
Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular Endpoint
Negative clinical trial results eliminate future commercial royalty cash flows for IONS and compress RPRX valuation, while removing a pipeline growth driver for NVS. — bearish pressure on NVS via cardiovascular pipeline revenue write-down.
Phase 3 HORIZON trial for pelacarsen failed primary endpoint
- SourcePhase 3 HORIZON trial for pelacarsen failed primary endpoint
- TransmissionNegative clinical trial results eliminate future commercial royalty cash flows for IONS and compress RPRX valuation, while removing a pipeline growth driver for NVS.
- SummaryNovartis' Phase 3 HORIZON trial for pelacarsen failed to reduce cardiovascular events. Royalty Pharma expects to recoup its $500 million capital investment despite the trial outcome. The failure affects commercialization prospects for lipoprotein(a)-lowering therapies.
- NVSDirect directional or hedged short
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- Fed officials or competing data may reframe the print
- NVS closes above pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- NVS price vs. pre-event level
- NVS volume vs. 20-day average
- 2Y/10Y Treasury yield direction
- DXY direction
- Fed funds futures repricing
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| IONS | Bearishagreed | 58.09 2026-09-04 | -2.38% | -11.45% | Pending |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen · polygon_news · 2026-09-04
Related catalysts
- 2026-09-24Ionis Reports Positive Phase III Endpoints in ALS and Kidney DiseaseAZN IONS+1.57%
- 2026-09-24Ionis reports positive Phase III trial results for partnered drugs in ALS and kidney diseaseIONS+1.57%
- 2026-09-24Ionis reports positive Phase III trial results for partnered drugs in ALS and kidney diseaseIONS+1.57%
- 2026-09-24Ionis Reports Positive Phase III Endpoints in ALS and Kidney DiseaseAZN IONS+1.57%
- 2026-09-24Ionis Announces Positive Phase III Trials for ALS and IgA Nephropathy TherapiesIONS+1.57%
- 2026-09-24Ionis Announces Positive Phase III Trials for ALS and IgA Nephropathy TherapiesIONS+1.57%
- 2026-09-24Ionis Announces Positive Phase III Results for Partnered FUS-ALS and IgAN ProgramsIONS+1.57%
- 2026-09-24Ionis Reports Positive Phase III Endpoints in ALS and Kidney DiseaseAZN IONS+1.57%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.